These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23169230)

  • 21. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
    Borgemeester RWK; van Laar T
    Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical considerations in the use of apomorphine injectable.
    Bowron A
    Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies.
    Borgemeester RWK; Diercks GFH; van Laar T
    Parkinsonism Relat Disord; 2021 Aug; 89():38-40. PubMed ID: 34218046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.
    Drapier S; Eusebio A; Degos B; Vérin M; Durif F; Azulay JP; Viallet F; Rouaud T; Moreau C; Defebvre L; Fraix V; Tranchant C; Andre K; Courbon CB; Roze E; Devos D
    J Neurol; 2016 Jun; 263(6):1111-9. PubMed ID: 27060084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 29. [Current treatment strategies for Parkinson's disease].
    Südmeyer M; Wojtecki L; Schnitzler A
    Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
    [No Abstract]   [Full Text] [Related]  

  • 30. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W; Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apomorphine therapy in Parkinson's disease: a review.
    Haq IU; Lewitt PA; Fernandez HH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
    Gunzler SA; Koudelka C; Carlson NE; Pavel M; Nutt JG
    Arch Neurol; 2008 Feb; 65(2):193-8. PubMed ID: 18268187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Limits of conventional oral and transdermal medication in Parkinson's disease].
    García-Ruiz PJ; Luquin MR
    Rev Neurol; 2012; 55 Suppl 1():S3-6. PubMed ID: 23169231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychosis in Parkinson's disease.
    Poewe W
    Mov Disord; 2003 Sep; 18 Suppl 6():S80-7. PubMed ID: 14502660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

  • 36. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apomorphine: North American clinical experience.
    Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
    Henriksen T
    Neurodegener Dis Manag; 2014; 4(3):271-82. PubMed ID: 25095821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA
    Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.